Why Cyclerion Therapeutics Stock Is Getting Hammered


Cyclerion Therapeutics Inc CYCN shares are trading lower by 43.33% to $0.53 during Thursday's trading session after the company announced a mitochondrial disease-focused strategy. The plan will include a 45% workforce reduction.

What Else?

Cyclerion Therapeutics says the company's workforce is being tailored to the mitochondrial disease-focused strategy, leading to a reduction of approximately 45%, to 16 full-time employees.

Cyclerion Therapeutics expects to take an aggregate charge for one-time employee-related costs of approximately $1.9 million that is expected to be incurred primarily in fourth-quarter 2022 and realize annual cash savings of approximately $4.1 million.

See Also: Here's How Much You'd Have Right Now If You Invested $1,000 In Apple Stock When Steve Jobs Left As CEO In 2011

According to data from Benzinga Pro, Cyclerion Therapeutics has a 52-week high of $3.05 and a 52-week low of $0.46.

Market News and Data brought to you by Benzinga APIs
Posted In: Penny StocksMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!